Videos

An oncologist reviews the use of nivolumab in the adjuvant setting for treating high-risk muscle invasive bladder cancer and experience from his practice.

Dr. Karim Chamie details the available primary and adjuvant treatments for muscle invasive bladder cancer.

Karim Chamie, MD, presents the case of a 75-year-old woman with high-risk muscle invasive bladder cancer.

“If you're looking at our results, in terms of the percent of authors who are female, the percent of first authors are female, or last authors who are female, we've seen growth in all 3 categories over the last 18 years,” said Megan Prunty, MD.

Closing out his discussion on saw palmetto extracts in benign prostatic hyperplasia and lower urinary tract symptoms, Bilal Chughtai, MD, shares practical advice for physicians.

A brief review of the safety profile associated with use of saw palmetto extracts in benign prostatic hyperplasia and lower urinary tract symptoms.

“I think that the most important thing to take home is that we all have implicit biases towards people who are underrepresented, whether it's women or minorities,” says Rena D. Malik, MD.

“The more you smoke, then the more prone you are to experience erectile dysfunction,” says Omar El Shahawy, MD, PhD.

“The important thing to know is that…we…aim to focus on the regions…that were not under the light of research education, in particular in the [genitourinary] space,” says Andrea Necchi, MD.

“The overall evidence in the global world literature is that saw palmetto can be effective,” says J. Curtis Nickel, MD, FRCSC.

“What we found was a signature that you can apply to patients to find out whether they're at high risk of these moderate or greater urinary side effects in the long term, and it did appear to depend on the type of radiation they were receiving,” says Amar U. Kishan, MD.

“I think there's a disconnect between the patients saying they're interested in these therapies, and the patients that actually go on to [receive] them,” says Jason Kim, MD.

“What's interesting in Dr Strum's analysis of these trials is that he not only looked at the English literature, which many of us are familiar with, but he looked at the many studies done in countries that were published in the non-English literature and never found [their] way into any of our analyses,” says J. Curtis Nickel, MD, FRCSC.

"Introducing something that with a prefashioned sling, [something] we're able to utilize with the patient in an ideal situation just under some deep sedation and local, really opened this up the ability for many more women to be treated and allowed many more physicians to be trained and to utilize this technology," says Howard B. Goldman, MD, FACS.

“We wanted to see whether certain variations and these micro-RNA binding sites could be associated with the risk of developing side effects,” says Amar U. Kishan, MD.

“Our goal was to educate these patients thoroughly on the risks and benefits of each of these therapies, and try to understand what guides their choice of third line therapy based on their lifestyle and what suits them,” says Anjali Kapur, MD.

“I think now the government has realized…the work that’s involved in this procedure…[and] we’re now being reimbursed at an appropriate level,” says David M. Albala, MD.

Expert insight on clinical trial data informing the use of saw palmetto extracts in benign prostatic hyperplasia and lower urinary tract symptoms.

A brief overview of regulation in nutraceuticals/food supplement use for patients with benign prostatic hyperplasia and lower urinary tract symptoms.

Interesting questions raised by a paper that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer and implications for integrating newer techniques into clinical practice.

“I think there is an urgency for us as urologists who are seeing many of these patients with kidney stones to be advocates, not just for the patients whom we're treating today, but for the populations in the future,” says Gregory Tasian, MD, MSc, MSCE.

Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.

A prostate cancer expert explains the potential advantages of sabizabulin, a new treatment for metastatic castration-resistant prostate cancer currently in a phase III clinical trial.

“The message is to please consider kidney preservation for these patients with TA low-grade disease,” says Seth P. Lerner, MD.

J. Curtis Nickel, MD, FRCSC, discusses the origins of saw palmetto as an herbal therapy and how it was developed to treat lower urinary tract symptoms.

“This is an attempt to provide the clinicians with the most recent available data and evidence, and therefore, tell them how this particular imaging…may affect their decision making for the treatment and management of their patients,” says Hossein Jadvar, MD, PhD.

Ulka Nitin Vaishampayan, MBBS, discusses the FGFR inhibitor erdafitinib and the importance of genetic/genomic testing in bladder cancer.

"These are fairly new technologies, but they've already made a dent into patient care," says Anthony Atala, MD.

“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.

“Andrea and I lead this from [a] President/Vice President standpoint, but we also have a group of leaders from around the world, really representing all ethnicities, genders and others, because we wanted to make sure [that] we're inclusive, andmeet the needs and expectations of everybody,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.